Site Search:

If you are visiting this website to learn more about the PACT Phase III Study of TNFerade™ in locally advanced pancreatic cancer please click here for information on trial sites and trial participation, call 1-888-344-6096 toll free, or click here to send an e-mail.
GenVec is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of our product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. Our lead product, TNFerade™, is currently in the pivotal Phase III PACT in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma, and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu, HSV-2, and foot and mouth disease.